ClinicalTrials.gg
Sign In

Myeloproliferative Disorders clinical trials

The registry lists 668 studies for Myeloproliferative Disorders across more than 10 countries. 111 are recruiting or about to start. 218 of them are mainly about Myeloproliferative Disorders (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12. Counting its 10 narrower conditions too, such as Leukemia, Myelogenous, Chronic, BCR-ABL Positive: 2,263 studies, 340 open.

ClinicalTrials.gov finds 2,563 studies for Myeloproliferative Disorders. How that becomes 665 here

This page counts the studies the registry files under Myeloproliferative Disorders, and those it files under no condition that list Myeloproliferative Disordersthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

  1. 2,563Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −1,574Filed under a narrower condition, counted on its own pageLeukemia, Myelogenous, Chronic, BCR-ABL Positive 794 · Primary Myelofibrosis 306 · Leukemia, Myeloid, Chronic-Phase 142 · Leukemia, Erythroblastic, Acute 133 · Blast Crisis 74 · Polycythemia Vera 74 · 4 more
  3. −324Match it another way7 name it in the title and 317 by a synonym or other text the search reads.
  4. 665The count on this page1 of them list Myeloproliferative Disorders in their own words; the registry filed them under no condition.

Get an email when these change. Save the Myeloproliferative Disorders studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed
357
Terminated
93
Recruiting
88
Active, not recruiting
47
Status unknown
31
Withdrawn
27

Phase

Phase 2
285
Phase 1
182
Phase 3
65
Phase 4
4
Early Phase 1
4

Where

United States
484
France
78
Italy
68
Canada
58
Germany
54
United Kingdom
44

Who runs them

Fred Hutchinson Cancer Center (44) · National Cancer Institute (NCI) (27) · Incyte Corporation (25) · City of Hope Medical Center (21) · Memorial Sloan Kettering Cancer Center (20) · M.D. Anderson Cancer Center (20) · Case Comprehensive Cancer Center (18) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (17)

What is being tested here

Drugs under test in Myeloproliferative Disorders studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

DrugOpenPhase 3All
Fludarabine6360
Cyclophosphamide6456
Azacitidine5015
Busulfan4334
Pacritinib4210
Venetoclax408
Mycophenolic Acid3529
CPX-351304
Ivosidenib304
Tacrolimus2224

Drug classes tested here Antimetabolites 12 open · Alkylating agents 11 open · Tyrosine kinase inhibitors (TKIs) 11 open · JAK inhibitors 6 open · Calcineurin inhibitors 3 open

Coming up

10phase 3 studies under way
49studies finish main data collection within a year1 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 88 Myeloproliferative Disorders studies recruiting now, 64 (73%) set no upper age limit and 18 (20%) stop at 75 or younger. 22 (25%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 6 (7%) take healthy volunteers.

Recruiting studies that take each age, of 88
AgeWomenMen
1019 (22%)19 (22%)
1885 (97%)85 (97%)
3085 (97%)85 (97%)
4082 (93%)82 (93%)
5082 (93%)82 (93%)
6579 (90%)79 (90%)
7577 (88%)77 (88%)
8569 (78%)69 (78%)

Across all 668 studies, recruiting or not: 29% stop at 75 or younger and 16% at 65; 29% take children; <1% are for women only and <1% for men only; 5% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Myeloproliferative Disorders studies take

Of 87 phase 2 interventional studies under Myeloproliferative Disorders, half reached primary completion within 68 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 167 mo37–140 · 40 studies——
Phase 1/262 mo30–125 · 23 studies——
Phase 268 mo37–111 · 87 studies—75 mo38–118 · 74 studies
Phase 351 mo37–77 · 20 studies——
Interventional, no phase54 mo20–128 · 26 studies——
Observational41 mo24–62 · 37 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 14, 2026.

Started recruiting2

Newly registered3

Studies

Recruiting first, then most recently updated. Showing 50 of 668. Browse all 668 → or search them.